Discover how tirzepatide, a diabetes drug, offers hope for congenital generalized lipodystrophy (CGL) treatment, potentially ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

“And so we cannot afford having a blurry picture of obesity.” It comes as the NHS has initiated the rollout of weight loss ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Tirzepatide does not yield a significant increase in pancreatitis risk despite elevating pancreatic enzyme levels, according to study findings published in Obesity Science and Practice. Tirzepatide, a ...

This repeated cross-sectional study including 69.2 million obesity management drug dispensed prescriptions revealed an increase from 0.76 million in July 2017 to 1.5 million in February 2024, with an ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Palatin Technologies (PTN – Research Report), retaining the price target ...